Source comparison
Melanotan-1 vs Melanotan-2 — The Research Comparison
Research published in the Journal of Medicinal Chemistry identified a single amino acid substitution that transforms melanocortin receptor selectivity. And with it, the entire safety and efficacy profile of synthetic melanotropins. That structural change separ
This comparison does not assign a generated winner or score.
- Research published in the Journal of Medicinal Chemistry identified a single amino acid substitution that transforms melanocortin receptor selectivity. And with it, the entire safety and efficacy profile of synthetic melanotropins. That structural change separates Melanotan-1 from Melanotan-2, two peptides that activate melanogenesis through fundamentally different pathways. One became an FDA-approved treatment for erythropoietic protoporphyria; the other remains confined to experimental research due to cardiovascular and sexual side effects that occur at therapeutic doses.
- At Real Peptides, we've observed hundreds of research teams evaluate the Melanotan-1 vs Melanotan-2 question. Not as interchangeable tanning agents, but as distinct melanocortin receptor modulators with non-overlapping applications. The difference isn't academic. It determines study design, dosage protocols, endpoint selection, and regulatory classification.
- What is the difference between Melanotan-1 and Melanotan-2?
- Melanotan-1 (afamelanotide) is a 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (α-MSH) with selective MC1 receptor agonism, producing melanogenesis with minimal off-target effects. Melanotan-2 is a cyclic 7-amino-acid peptide with broad melanocortin receptor activity (MC1, MC3, MC4, MC5), producing melanogenesis alongside appetite suppression, sexual arousal, and cardiovascular effects. Melanotan-1 has FDA approval; Melanotan-2 does not.
- The Melanotan-1 vs Melanotan-2 comparison isn't about which peptide tans faster. It's about receptor selectivity and the cascade of systemic effects that follow. Melanotan-1 binds preferentially to MC1 receptors on melanocytes, triggering eumelanin synthesis without significantly engaging MC3 or MC4 receptors in the hypothalamus or cardiovascular tissue. Melanotan-2's cyclic structure allows it to activate all five melanocortin receptor subtypes, which is why the same dose that induces tanning also reduces food intake and elevates blood pressure. This article covers the structural mechanisms driving receptor selectivity, the clinical and experimental evidence distinguishing their effects, and the practical protocol differences researchers encounter when working with each peptide.